peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma: Increase of the number of shares and votes

31 Oct 2022, 17:00
Regulatory information

Lund, Sweden, October 31, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the number of outstanding votes in Hansa have increased during the month of October 2022 as a result of the conversion of a total of 7,733 class C shares to a total of 7,733 ordinary shares.

The conversion was carried out by Hansa in order to deliver ordinary shares to participants in Hansa’s incentive program adopted at the annual general meeting in 2019. The total number of votes in Hansa has therefore increased while the total number of shares remain unchanged.

As of today, the total number of registered and outstanding shares of Hansa amounts to 47,186,130, whereof 44,595,851 are ordinary shares and 2,590,279 are class C shares. As of today, the number of votes in Hansa amounts to 44,854,878.9, and the registered share capital amounts to SEK 47,186,130.

This information is information that Hansa Biopharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on October 31, 2022, at 17:00 CET.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at